لخّصلي

The PD-1/PD-L1 pathway regulates immune tolerance in the tumor microenvironment.PD-1 and its ligands, PD-L1 or PD-L2, control T cell activation, proliferation, and cytotoxicity, impacting anti-tumor immune responses.PD-1 inhibits adaptive and innate immune responses, It has dual roles, beneficial in reducing ineffective immune responses and harmful by promoting tumor cell growth.

The PD-1/PD-L1 pathway regulates immune tolerance in the tumor microenvironment. PD-1 and its ligands, PD-L1 or PD-L2, control T cell activation, proliferation, and cytotoxicity, impacting anti-tumor immune responses.PD-1 inhibits adaptive and innate immune responses, It has dual roles, beneficial in reducing ineffective immune responses and harmful by promoting tumor cell growth.
PD-L1 serves as an "adaptive immune mechanism" for tumors to evade immune responses. It promotes tumor growth by activating proliferative and survival pathways, contributing to tumor progression. Additionally, PD-L1 exerts non-immune proliferative effects on various tumor cell types. PD-1 and CTLA-4 act as immune checkpoints, inhibiting T-cell function. Inhibiting these checkpoints may reactivate T cells, enhancing cancer cell elimination.
PD-1 inhibition promotes an effective immune response against cancer cells.

the expression levels of PD-1 and PD-L1 in tumor tissues can serve as biomarkers for diagnosing certain types of cancer. High levels of PD-L1 expression, for example, may indicate that a tumor is using the PD-L1 pathway to evade the immune system. This information can help clinicians in making accurate diagnoses and determining appropriate treatment strategies.can also provide valuable prognostic information. Patients with tumors expressing high levels of PD-L1 may have a poorer prognosis, as this indicates that the tumor has developed mechanisms to suppress the immune response. Prognostic information derived from the PD-1/PD-L1 pathway can help guide treatment decisions and monitor disease progression.he PD-1/PD-L1 pathway has revolutionized cancer treatment through the development of immune checkpoint inhibitors (ICIs). Drugs that target either PD-1 or PD-L1, such as pembrolizumab and nivolumab, have shown remarkable efficacy in treating various types of cancer, including melanoma, lung cancer, and bladder cancer. By blocking the interaction between PD-1 and PD-L1, these drugs unleash the immune system to attack and destroy cancer cells. The use of ICIs has significantly improved treatment outcomes and survival rates for many cancer patients.